Consegna Pharma Highlights Innovative Modeling and Simulation Strategy as FDA Concurs with Regulatory Pathway for CP217 to Prevent Fentanyl Epidemic Deaths Larry ZanaMay 6, 2026
Consegna Pharma Acquires Fathom Pharma to Strengthen Initiatives that Address the Opioid Crisis Larry ZanaApril 19, 2022
Consegna Pharma Receives NIH Research Grant to Develop CP216, a Sustained-Release Naloxone Treatment for Opioid Overdose Reversal Larry ZanaDecember 12, 2019
